We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Lapatinib-Associated Toxicity and Practical Management Recommendations.
- Authors
Moy, Beverly; Goss, Paul E.
- Abstract
Lapatinib is an oral receptor tyrosine kinase inhibitor, inhibiting both the ErbB-1 and ErbB-2 receptors. Lapatinib has been shown to have activity in ErbB-2- overexpressing breast cancer in several phase II and III clinical trials. Specifically, lapatinib is effective in patients with metastatic breast cancer, with inflammatory breast cancer, and possibly, with brain metastases. An ongoing clinical trial and another anticipated clinical trial will investigate lapatinib as adjuvant treatment in early-stage disease. Lapatinib has specific toxicities, the most common being diarrhea and rash. Cardiac toxicity is rarely seen with lapatinib. This paper reviews lapatinib-associated toxicities and provides practical management recommendations based on available data.
- Subjects
PROTEIN-tyrosine kinases; ANTINEOPLASTIC agents; ADJUVANT treatment of cancer; CANCER treatment; DRUG side effects; BREAST cancer
- Publication
Oncologist, 2007, Vol 12, Issue 7, p756
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1634/theoncologist.12-7-756